Please ensure Javascript is enabled for purposes of website accessibility

Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

By Keith Speights and Brian Orelli, PhD - Apr 10, 2021 at 7:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the three clearly has the most upside potential.

GlaxoSmithKline (GSK 0.51%), Vir Biotechnology (VIR 1.57%), and Eli Lilly (LLY 0.15%) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.

Keith Speights: Speaking of GlaxoSmithKline...The big drugmaker, along with its much smaller partner, Vir Biotechnology, ticker for Vir is V-I-R, and also along with Eli Lilly, ticker there is LLY, these companies recently reported positive results, I think just earlier this week, from a phase II study that evaluated a combination of the company's drugs in treating mild-to-moderate cases of COVID.

What's your take on those results, Brian, and of these three stocks, GlaxoSmithKline, Eli Lilly, Vir Biotechnology, which do you think is likely to be the biggest winner over the next few years?

Brian Orelli: I like this population that they're treating this mild-to-moderate better than the studies for other antibodies where they've looked at more patients that were more likely to become advanced. If the doctors didn't have to figure out whether they were low-risk or high-risk, that's to the company's advantage, because then the doctors can just basically give it to everybody.

This clinical trial looked at the viral loads, and it reduced persistently high viral loads by 70%, I think that was on day 7. Then they also looked at absolute viral loads, and they were reduced on day 3 and day 5 and day 7. Viral loads are important for spread, but it's a surrogate for sickness, but no one was hospitalized in either arm, so either the people who got the drug or the people who got the placebo. It's hard to know exactly how much is this actually benefiting the companies.

Based on size alone, Vir's obviously the winner here because it's a very small company, and Glaxo and Lilly are giant companies, so this isn't going to benefit them nearly as much. Eli Lilly's antibody is not being used on its own anymore because of the variance, so maybe in theory it benefits a little bit, but Eli Lilly has a second antibody that it's testing in combination with this antibody.

Then part of the issue just is that they haven't done any head-to-head studies of the different antibodies, so it's really hard to know which antibodies or combination antibodies would be most beneficial to patients in the long run. Maybe those studies will eventually come.

Speights: Basically, we're seeing the trade-off between risk and reward here. Obviously, Eli Lilly and GlaxoSmithKline are much larger companies -- they have a lot of products already on the market so they're not going to get as big of a bump, even if all goes well with this combo therapy, but they're also not nearly as risky as Vir Biotechnology. But for that additional risk with Vir, you get the possibilities of much greater returns over the next few years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$25.87 (1.57%) $0.40
GSK Stock Quote
$43.75 (0.51%) $0.22
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$324.71 (0.15%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.